Ascendis Pharma A/S (NASDAQ:ASND) Receives Average Recommendation of “Moderate Buy” from Analysts

Ascendis Pharma A/S (NASDAQ:ASND) has earned an average recommendation of “Moderate Buy” from the thirteen research firms that are presently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a hold rating and twelve have given a buy rating to the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $195.92.

A number of brokerages recently weighed in on ASND. The Goldman Sachs Group raised their target price on shares of Ascendis Pharma A/S from $180.00 to $200.00 and gave the stock a “buy” rating in a report on Tuesday, September 17th. Cantor Fitzgerald reissued an “overweight” rating and set a $170.00 price objective on shares of Ascendis Pharma A/S in a research note on Monday, September 16th. JPMorgan Chase & Co. cut their target price on Ascendis Pharma A/S from $180.00 to $174.00 and set an “overweight” rating on the stock in a research report on Wednesday. Jefferies Financial Group lifted their price target on Ascendis Pharma A/S from $174.00 to $196.00 and gave the stock a “buy” rating in a research note on Tuesday, August 13th. Finally, Wells Fargo & Company upped their price objective on shares of Ascendis Pharma A/S from $264.00 to $289.00 and gave the company an “overweight” rating in a research note on Tuesday, September 17th.

Ascendis Pharma A/S Stock Performance

ASND opened at $130.32 on Friday. The company has a market capitalization of $7.59 billion, a PE ratio of -13.56 and a beta of 0.64. The stock’s fifty day moving average is $134.73 and its 200-day moving average is $134.52. Ascendis Pharma A/S has a one year low of $85.70 and a one year high of $161.00.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its quarterly earnings results on Tuesday, September 3rd. The biotechnology company reported ($2.05) EPS for the quarter, missing the consensus estimate of ($1.54) by ($0.51). The business had revenue of $38.75 million for the quarter, compared to analysts’ expectations of $94.74 million. On average, equities research analysts forecast that Ascendis Pharma A/S will post -7.2 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in ASND. Hennion & Walsh Asset Management Inc. increased its stake in shares of Ascendis Pharma A/S by 14.3% in the first quarter. Hennion & Walsh Asset Management Inc. now owns 7,034 shares of the biotechnology company’s stock worth $1,063,000 after acquiring an additional 882 shares during the last quarter. Private Ocean LLC purchased a new stake in shares of Ascendis Pharma A/S during the 1st quarter worth about $36,000. Matisse Capital lifted its holdings in shares of Ascendis Pharma A/S by 2.6% during the 1st quarter. Matisse Capital now owns 35,540 shares of the biotechnology company’s stock valued at $5,373,000 after buying an additional 905 shares during the last quarter. BNP Paribas Financial Markets grew its stake in shares of Ascendis Pharma A/S by 4,231.4% in the 1st quarter. BNP Paribas Financial Markets now owns 75,540 shares of the biotechnology company’s stock valued at $11,419,000 after buying an additional 73,796 shares in the last quarter. Finally, Tobam increased its holdings in Ascendis Pharma A/S by 41.1% in the first quarter. Tobam now owns 2,163 shares of the biotechnology company’s stock worth $327,000 after buying an additional 630 shares during the last quarter.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.